CuraTeQ–BioFactura biosimilar tie-up ends as Aurobindo reprioritises pipeline

CuraTeQ Biologics Pvt Ltd, a wholly owned subsidiary of

, has mutually terminated its licensing agreement with US-based BioFactura Inc for BFI-751, a proposed biosimilar of ustekinumab (Stelara). The termination follows a strategic portfolio review and is positioned as a resource-allocation decision rather than a shift away from biosimilars. The pact, signed in July 2023, was intended to support commercialisation in regulated markets, with BioFactura eligible for licence fees tied to development and commercial milestones. CuraTeQ retained global manufacturing rights under a profit-sharing structure, but the arrangement will now end effective December 27, 2025. Aurobindo stated the decision is not expected to have a material impact on its broader biosimilars strategy and reiterated its longer-term commitment to the segment. It also clarified BioFactura is not part of the promoter/promoter group and the transaction is not a related-party matter. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.